株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

間葉系幹細胞 (MSC) :製品・技術の進歩と各種用途

Mesenchymal Stem Cells - Advances & Applications (2018)

発行 BIOINFORMANT WORLDWIDE, LLC 商品コード 234291
出版日 ページ情報 英文 216 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.96円で換算しております。
Back to Top
間葉系幹細胞 (MSC) :製品・技術の進歩と各種用途 Mesenchymal Stem Cells - Advances & Applications (2018)
出版日: 2018年01月23日 ページ情報: 英文 216 Pages
概要

当レポートでは、間葉系幹細胞 (MSC) の市場を調査し、幹細胞および間葉系幹細胞 (MSC) の概要、各種タイプ、臨床的用途の発展と推移、臨床研究・臨床開発の動向、上市済み製品の概要、各種用途・対応疾患の動向、企業間の提携などの取り組み、主要企業・製品のプロファイルなどをまとめています。

第1章 レポート概要

第2章 イントロダクション

第3章 先端医療医薬品 (ATMP:ADVANCED THERAPY MEDICINAL PRODUCTS)

  • 主な対象分野
  • 上市済みATMPの価格
  • FDA承認済みATMP
  • EC承認済みATMP

第4章 幹細胞:概要

  • 胚性幹細胞 (ESC)
  • 人工多能性幹細胞 (iPSC)
  • 幹細胞由来の特殊化細胞の各種タイプ
  • 人体の幹細胞の各種タイプ
    • ヒト胚性幹細胞 (hESC)
    • EG細胞
    • 胎生幹細胞
    • 臍帯幹細胞
  • 成体幹細胞
    • 造血幹細胞 (HSC)
    • 間葉系幹細胞 (MSC)
    • 神経幹細胞 (NSC)
  • 各種幹細胞の特徴
  • 医療における用途

第5章 間葉系幹細胞 (MSC):概要

  • MSCの新たな名称
  • MSCの機能
  • MSCのソース
  • hMSCの分離・培養
  • MSCの各種タイプの特徴
  • hMSCで治療可能な慢性疾患
  • MSC細胞治療の対象となる一般的な疾患
  • 細胞治療におけるMSCのメリット
  • MSCと他の幹細胞タイプとの比較
  • 自家MSCの欠点と同種MSCのメリット
  • MSCの作用機序
  • 組織再生
  • 免疫修飾
  • MSCの製造

第6章 MSCの臨床的用途

  • GvHD
  • 心臓血管修復
  • 肝疾患
  • 骨/軟骨疾患のためのMSC
  • 承認済みMSC製品
    • Cartistem
    • Stempeucel
    • MPC (Mesenchymal Precursor Cell):Mesoblast
    • Cupistem
    • Prochymal
    • AlloStem
    • Cellgram-AMI
    • Osteocel Plus
    • Trinity Evolution
    • CardioRel
    • Temcell
  • MSCを含む骨基質
    • コスト
    • 組織工学による整形外科製品候補
  • 承認済み細胞治療製品の価格

第7章 幹細胞研究の出版・資金・特許

  • MSCに関する科学論文
  • 世界の幹細胞研究
  • NIHのMSC研究資金
  • 特許環境

第8章 MSC関連の臨床試験:概要

  • 現在の臨床試験シナリオ
  • MSC関連の臨床試験の地域的シェア
  • 臨床試験のソース
  • 現在試験中の対応疾患
  • 現行の臨床試験
  • 臨床試験のこれまでの成果
  • 大学主導の主な臨床試験
  • 企業主導の主な臨床試験
  • 心血管疾患
  • 変形性関節症
  • 創傷治癒
  • 肝疾患
  • 肺疾患
  • 眼障害
  • 腎障害
  • 糖尿病
  • 移植片対宿主病 (GvHD)
  • 炎症性腸疾患
  • 多発性硬化症
  • 特定疾患におけるMSC臨床研究の状況
    • 移植片対宿主病 (GvHD)
    • OA & RA
    • 炎症性気道・肺疾患
    • 多発性硬化症 (MS)
    • 炎症性腸疾患 (IBD)
    • 遺伝子組み換えMSC

第9章 提携の取り組み

第10章 市場分析

第11章 企業プロファイル

目次

Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially other cell types.

In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications.

Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth. Additionally, MSCs well-suited for use in the exponential growth area of 3D printing, because of their capacity to form structural tissues.

Growing attention is now being given to manufacturing technologies to support commercial-scale production of MSCs. Numerous market competitors are also exploring commercialization strategies for MSC-derived exosomes, because exosomes represent a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.

As the most common stem cell type being used in regenerative medicine, there is substantial potential for growth within the MSC market. Today, there are more than 40,000 scientific publications published about the cell type[1], more than 800 clinical trials underway worldwide[2], and Google Trend data reveals that MSC searches are more than twice as common as the next most common adult stem cell type[3].

Burgeoning Market for Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are the most utilized cell type within the regenerative medicine industry. To support this rapidly expanding marketplace, this 200+ page global strategic report presents trend rate data for MSC market, including rates of MSC patents, grants, scientific publications, and clinical trials, as well as social analytics that identify online behavior related to MSCs.

The report describes the current status of mesenchymal stem cell (MSC) research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and uses of MSCs in cell therapy. It explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 73 leading competitors within the MSC marketplace.

Because MSC therapy is an integrated component of Advanced Therapy Medicinal Products (ATMPs), this market report also provides an introduction to ATMPs.

For pharmaceutical companies, the report reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies. With “Big Pharma” diversifying their product development pipelines by investing in cell therapy companies, MSC companies now represent promising candidates for collaboration, investment, and acquisition.

Based in Washington, DC, BioInformant is first and only market research firm to specialize in the stem cell industry. Unlike other publishers that hire analysts from foreign countries, BioInformant is an American-based company with more than a decade of experience with tracking the stem cell market (2006 to present). BioInformant compiled this global strategic report using interviews with more than 90 individuals from across the stem cell industry.

BioInformant conducted interviews with representatives from Cynata Therapeutics (first company to bring a iPSC-derived MSC therapeutic product into a clinical trial), RoosterBio (global leader in MSC manufacturing technology that can produce to tens of billions of cells in suspension bioreactors), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), BioEden (leading company preserving MSCs derived from dental tissues), Regenexx (world's leading provider of MSC therapies for orthopedic applications), and many more.

The report also incorporates secondary findings from SEC filings, company websites, press releases, investor presentations, government policy documents, Google Trends, and Google Adwords.

Footnotes:

[1] PubMed.gov Search; Date: 01/14/2017. Search terms: “mesenchymal stem cell” OR “mesenchymal stem cells” OR “mesenchymal stromal cell” OR “mesenchymal stromal cells”.

[2] ClinicalTrials.gov Search; Date: 01/14/2017. Search terms: “mesenchymal stem cell” OR “mesenchymal stem cells” OR “mesenchymal stromal cell” OR “mesenchymal stromal cells”.

[3]Google Trends Search; Date: 01/14/2017. Search Terms Compared: “mesenchymal stem cells” vs. “hematopoietic stem cells” vs. “neural stem cells”.

Table of Contents

1. REPORT OVERVIEW

  • 1.1. Statement of the Report
  • 1.2. Executive Summary

2. INTRODUCTION

3. ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPs)

  • 3.1. Major Therapeutic Areas of Interests in ATMPs Sector
  • 3.2. Price of Market-Stage ATMPs
  • 3.3. FDA-Approved ATMPs
  • 3.4. EC-Approved ATMPs

4. STEM CELLS: A BRIEF OVERVIEW

  • 4.1. Embryonic Stem Cells (ESCs)
  • 4.2. Induced Pluripotent Stem Cells (iPSCs)
  • 4.3. Types of Specialized Cells Derived from Stem Cells
  • 4.4. Types of Stem Cells in Human Body
    • 4.4.1. Human Embryonic Stem Cells (hESCs)
    • 4.4.2. Embryonic Germ Cells (EG-Cells)
    • 4.4.3. Fetal Stem Cells
    • 4.4.4. Umbilical Cord Stem Cells
  • 4.5. Adult Stem Cells
    • 4.5.1. Hematopoietic Stem Cells (HSCs)
    • 4.5.2. Mesenchymal Stem Cells (MSCs)
    • 4.5.3. Neural Stem Cells (NSCs)
  • 4.6. Characteristics of Different Types of Stem Cells
  • 4.7. Applications of Stem Cells in Medicine

5. MESENCHYMAL STEM CELLS (MSCs): A DETAILED OVERVIEW

  • 5.1. A New Name for MSCs
    • 5.1.1. History and Timeline of MSCs Nomenclature
  • 5.2. Functions of MSCs
  • 5.3. Sources of MSCs
  • 5.4. Isolation and Culturing of hMSCs
    • 5.4.1. Cell Surface Markers in MSCs
    • 5.4.2. In Vitro Differentiation Potential of MSCs
  • 5.5. Key Features of Different Types of MSCs
  • 5.6. Chronic Diseases Treatable by hMSCs
  • 5.7. Common Diseases Registered for MSC-Based Cell Therapy
  • 5.8. Advantages of MSCs in Cell Therapy
  • 5.9. Comparison of MSCs with Other Stem Cell Types
  • 5.10. Drawbacks of Autologous MSCs and Advantages of Allogeneic MSCs
    • 5.10.1. Application Strategies for Allogeneic MSCs
  • 5.11. Mechanism of Action of MSCs in Treating Diseases
  • 5.12. Tissue Regeneration
  • 5.13. Immune Modulation
  • 5.14. Manufacture of MSCs
    • 5.14.1. Safety and Potency Assays
    • 5.14.2. Surface Markers of MSC
    • 5.14.3. BM-MNC Isolation and Plating
    • 5.14.4. Passaging and Harvesting
    • 5.14.5. Cryopreservation of MSCs
    • 5.14.6. Donor Eligibility and Cell Collection
    • 5.14.7. Regulatory Framework of MSC Therapies
    • 5.14.8. Contract Development and Manufacturing Organizations (CDMO)

6.1. MSCs for GvHD

  • 6.2. MSCs for Cardiovascular Repair
  • 6.3. MSCs for Liver Disease
  • 6.4. MSC for Bone/Cartilage Disease
  • 6.5. Approved MSC-Based Products
    • 6.5.1. Cartistem
    • 6.5.2. Stempeucel
    • 6.5.3. Mesenchymal Precursor Cells (MPCs) from Mesoblast
    • 6.5.4. Cupistem
    • 6.5.5. Prochymal
    • 6.5.6. AlloStem
    • 6.5.7. Cellgram-AMI
    • 6.5.8. Osteocel Plus
    • 6.5.9. Trinity Evolution
    • 6.5.10. CardioRel
    • 6.5.11. Temcell
  • 6.6. Bone Matrices Containing MSCs
    • 6.6.1. Cost of Bone Matrices Containing MSCs
    • 6.6.2. Tissue Engineered Orthopedic Product Candidates Containing MSCs
  • 6.7. Pricing of Approved Cell Therapy Products

7. STEM CELL RESEARCH PUBLICATIONS, FUNDING AND PATENTS

  • 7.1. Volume of Scientific Papers Published on MSCs
    • 7.1.1. Number of Publications on MSCs by Major Applications
  • 7.2. Stem Cell Research around the World
  • 7.3. NIH Funding for MSCs Research
  • 7.4. Stem Cell Patents Landscape

8. CLINICAL TRIALS INVOLVING MSCS: AN OVERVIEW

  • 8.1. Current Clinical Trial Scenario
  • 8.2. Geographical Share of MSC Clinical Trials
    • 8.2.1. Number of Clinical Trials using MSCs by Geography/Country
  • 8.3. Sources of MSCs for Current Clinical Trials
  • 8.4. Diseases Addressed by MSCs in the Ongoing Clinical Trials
  • 8.5. Active Clinical Trials using MSCs
  • 8.6. MSC Clinical Trial Outcomes, 2011-2016
  • 8.7. Selected Clinical Trials Sponsored by Universities
    • 8.7.1. Celal Bayar University (NCT02824393)
    • 8.7.2. University of Jordan (NCT02118519)
    • 8.7.3. Ankara University (NCT03106662)
    • 8.7.4. University Hospital of Liege (NCT00504803)
    • 8.7.5. Acibadem University (NCT02285673)
    • 8.7.6. University of Sao Paulo (NCT01297972)
    • 8.7.7. Cairo University (NCT02387749)
  • 8.8. Selected Clinical Trials Sponsored by Cell Therapy Companies
    • 8.8.1. Scinow Biotechnology Co., Ltd. (NCT03184935)
    • 8.8.2. Mesoblast Ltd. (NCT00294112)
    • 8.8.3. Cellular Biomedicine Group Ltd. (NCT01809769)
    • 8.8.4. Alliancells Bioscience Corporation Ltd. (NCT01573923)
    • 8.8.5. Pharmicell Co., Ltd. (NCT01676441)
    • 8.8.6. Shenzhen Hometcorn Biotechnology Co., Ltd.
    • 8.8.7. Sclnow Biotechnology Co., Ltd. (NCT03180450)
  • 8.9. Clinical Trials using MSCs for Cardiovascular Diseases
    • 8.9.1. Corporate Investment in Cardiovascular Diseases using MSC Therapy
      • 8.9.1.1. MPC-150-IM from Mesoblast
      • 8.9.1.2. CLBS10 from Caladrius
      • 8.9.1.3. C-Cure from Celyad
      • 8.9.1.4. Ixmyelocel-T from Vericel
      • 8.9.1.5. MultiStem from Athersys
  • 8.10. MSCs for Osteoarthritis
  • 8.11. MSCs in Wound Healing
  • 8.12 MSCs for Liver Diseases
  • 8.13. MSCs for Lung Disorders
  • 8.14. Clinical Trials using MSCs for Eye Disorders
  • 8.15 MSCs for Kidney Disorders
  • 8.16. MSCs for Diabetes
  • 8.17. MSCs for Graft vs. Host Disease (GvHD)
  • 8.18. MSCs for Inflammatory Bowel Diseases
  • 8.19. MSCs for Multiple Sclerosis
  • 8.20. Status of MSC Clinical Research in Specific Diseases
    • 8.20.1. Graft v. Host Disease (GvHD)
    • 8.20.2. OA & RA
    • 8.20.3. Inflammatory Airway and Pulmonary Diseases
    • 8.20.4. Multiple Sclerosis (MS)
    • 8.20.5. Inflammatory Bowel Disease (IBD)
    • 8.20.6. Genetically Engineered MSCs

9. PARTNERING ACTIVITIES IN CELL THERAPY SECTOR

  • 9.1. Collaboration between Lonza and Nikon
  • 9.2. Hitachi's Purchase of PCT from Caladrius Biosciences
  • 9.3. Collaboration between Regeneus Ltd. and Asahi Glass. Co. on Progenza
  • 9.4. Collaboration between RepliCel Life Sciences and Shiseido Co., Ltd.
  • 9.5. Collaboration between SanBio Life Sciences and Sumitomo
  • 9.6. Partnership and License Agreement between Healios K.K. and Athersys Inc.
  • 9.7. Cell Therapy Ltd.'s License to Daiichi Sankyo
  • 9.8. TiGenix's License to Takeda Pharmaceuticals
  • 9.9. Celyad's License to Ono Pharmaceuticals
  • 9.10. Collaboration Kolon Life Sciences and Mitsubishi Tanabe
  • 9.11. Collaboration between Steminent Biotherapeutics and ReproCELL Inc.
  • 9.12. Kite Pharma's Partnership with Daiichi Sankyo
  • 9.13. Acquisition of Cellular Dynamics by Fujifilm Holdings
  • 9.14. License Agreement between Cynata Therapeutics and Fujifilm
  • 9.15. Gilead to Acquire Kite Pharma
  • 9.16. Big Pharma's Strategy in Advanced Therapy Sector
    • 9.16.1. Collaboration between Sangamo and Pfizer
    • 9.16.2. Acquisition of 3D Printing Systems from Tissue Regeneration Systems by DePuy Synthes Products (J&J)
    • 9.16.3. New JLABS Opened by J&J
    • 9.16.4. Collaboration between GSK and Miltenyl Biotec
  • 9.17. Big Pharma's Interest in Cell Therapy
    • 9.17.1. GlaxoSmithKline (GSK)
    • 9.17.2. Pfizer
    • 9.17.3. Novartis
    • 9.17.4. AstraZeneca
    • 9.17.5. Roche
    • 9.17.6. Johnson & Johnson
    • 9.17.7. Sanofi
  • 9.18. Big Pharma Strategy in Advanced Therapies
    • 9.18.1. Value of Big Pharma Deals in Cell and Gene Therapy
  • 9.19. Recent Events in Advanced Therapies Sector
  • 9.20. Geographical Distribution of Cell Therapy Companies

10. MARKET ANALYSIS

11. COMPANY PROFILES

  • 11.1. AdiCyte
  • 11.2. AdiSave
  • 11.3. AlloSource Inc.
    • 11.3.1. AlloStem
  • 11.4. American CryoStem Corporation
    • 11.4.1. Clinical Adipose-Tissue Platform
  • 11.5. Anterogen Co., Ltd.
    • 11.5.1. Cupistem Injection
  • 11.6. Apceth Biopharma GmbH
    • 11.6.1. Apceth's Allogeneic MSC Platform
      • 11.6.2. Apceth's Genetically-Engineered MSCs
  • 11.7. Athersys Inc.
    • 11.7.1. MultiStem
  • 11.8. Astarte Biologics Inc.
  • 11.9. BioCardia Inc.
    • 11.9.1. Product Pipeline
  • 11.10. BioRestorative Therapies Inc.
    • 11.10.1. brtxDISC
    • 11.10.2. ThermoStem Program
  • 11.11. Bone Therapeutics SA
    • 11.11.1. Collaborators
  • 11.12. Brainstorm Cell Therapeutics
    • 11.12.1. NurOwn Technology
  • 11.13. Caladrius Biosciences Inc.
    • 11.13.1. CLBS03
    • 11.13.2. CLBS12
  • 11.14. Capricor Therapeutics Inc.
    • 11.14.1. CAP-1002
    • 11.14.2. CAP-2003
  • 11.15. Cell Applications Inc.
  • 11.16. Cell Cure Neurosciences Ltd.
    • 11.16.1. OpRegen
  • 11.17. CellGenix Technologie Transfer GmbH
    • 11.17.1. Cell Types Offered
    • 11.17.2. CellGro Cytokines
    • 11.17.3. Serum-Free Media
    • 11.17.4. Supplements and Cells
  • 11.18. CellProthera SAS
    • 11.18.1. ProtheraCytes
  • 11.19. Celltex Therapeutics Corporation
  • 11.20. Cellular Dynamics International Inc.
  • 11.21. Celprogen Inc.
  • 11.22. Cell Therapies Pty Ltd.
    • 11.22.1. Contract Manufacturing Services
    • 11.22.2. Apheresis Management Services
    • 11.22.3. Clinical Trial Support Services
    • 11.22.4. Consultancy & Advisory Services
  • 11.23. Celvive Inc.
    • 11.23.1. The StemCell Bag
  • 11.24. Cesca Therapeurics Inc.
    • 11.24.1. CAR-TXpress
    • 11.24.2. AutoXpress (AXP)
    • 11.24.3. Point-of-Care Solutions for Cell-Based Therapies (PXP)
    • 11.24.4. CellXpress
  • 11.25. Celyad SA
  • 11.26. Cyagen Biosciences Inc.
    • 11.26.1. Cells
    • 11.26.2. Media
  • 11.27. Cynata Therapeucics Ltd.
    • 11.27.1. Cymerus Platform Technology
  • 11.28. Cytori Therapeutics Inc.
    • 11.28.1. Cytori Cell Therapy
  • 11.29. Escape Therapeutics Inc.
  • 11.30. Future Health BioBank
  • 11.31. Gamida Cell Ltd.
    • 11.31.1. NAM Technology
    • 11.31.2. NiCord
    • 11.31.3. Cordin
    • 11.31.4. NAM-NK Cells
  • 11.32. Intercytex Ltd.
    • 11.32.1. ICH-RHY
  • 11.33. International Stem Cell Corp.
  • 11.34. Invitrx Therapeutics Inc.
    • 11.34.1. Therapeutic Procedures
    • 11.34.2. Invitra ECM Suspension
    • 11.34.3. Cosmetic Procedures
  • 11.35. JCR Pharmaceuticals Co., Ltd.
    • 11.35.1. Temcell HS Inj.
  • 11.36. Kadimastem Ltd.
    • 11.36.1. Solution for Diabetes
    • 11.36.2. Solution for Neurodegenerative Diseases
  • 11.37. Kiadis Pharma N.V.
    • 11.37.1. ATIR101
    • 11.37.2. ATIR201
  • 11.38. Kite Pharma Inc.
    • 11.38.1. Kite Pharma's Research
  • 11.39. Life Sciences Inc.
    • 11.39.1. Technology
    • 11.39.2. RCT-01
    • 11.39.3. RCS-01
    • 11.39.4. RCH-01
    • 11.39.5. RCI-02
  • 11.40. Living Cell Technologies Ltd.
    • 11.40.1. NTCELL
  • 11.41. Lonza Group Ltd.
  • 11.42. Magenta Therapeutics Inc.
    • 11.42.1. Magenta's Stem Cell Platform
  • 11.43. Medeor Therapeutics Inc.
    • 11.43.1. MDE-10X
  • 11.44. Medipost Co., Ltd.
    • 11.44.1. Cartistem
    • 11.44.2. Pneumostem
    • 11.44.3. Neurostem
  • 11.45. Mesoblast Inc.
    • 11.45.1. MPC-150-IM
    • 11.45.2. MPC-300-IV
    • 11.45.3. MPC-06-ID
    • 11.45.4. MSC-100-IV
    • 11.45.5. Temcell HS Injection
  • 11.46. NuVasive Inc.
    • 11.46.1. Osteocel
  • 11.47. Neuralstem Inc.
    • 11.47.1. NSI-189
  • 11.48. Octane Biotech Inc.
    • 11.48.1. Turn-Key Production System for Cell and Tissue Therapy
    • 11.48.2. Automated Bioreactors
    • 11.48.3. Atomically Enhanced Implants
    • 11.48.4. Drug-Enhanced Implants
    • 11.48.5. Cell-Enhanced Implants
  • 11.49. Organogenesis Inc.
    • 11.49.1. Apligraf
    • 11.49.2. Dermagraft
  • 11.50. Orthofix International N.V.
    • 11.50.1. BioStim
    • 11.50.2. Biologics
      • 11.50.2.1. Trinity ELITE
      • 11.50.2.2. Trinity Evolution
      • 11.50.2.3. VersaShield
      • 11.50.2.4. Collage
      • 11.50.2.5. AlloQuent
  • 11.51. Osiris Therapeutics Inc.
    • 11.51.1. Grafix
    • 11.51.2. BIO4
    • 11.51.3. Stravix
    • 11.51.4. Cartiform
  • 11.52. OxStem Ltd.
  • 11.53. PharmaCell B.V.
  • 11.54. Pharmicell Co. Ltd.
    • 11.54.1. Cellgram-AMI
  • 11.55. Pluristem Therapeutics Inc.
    • 11.55.1. PLX Products
    • 11.55.2. PLX-PAD
    • 11.55.3. PLX-R18
    • 11.55.4. Prochymal
  • 11.56. Precious Cells International Ltd.
  • 11.57. Promethera Biosciences S.A.
    • 11.57.1. HepaStem for ACLF
    • 11.57.2. HepaStem for NASH
    • 11.57.3. H2Stem
    • 11.57.4. Heparesc
  • 11.58. Provia Laboratories, LLC
  • 11.59. Regen BioPharma Inc.
    • 11.59.1. HemaXellerate (Phase I/II)
  • 11.60. Regeneus Ltd.
    • 11.60.1. Progenza
    • 11.60.2. RGSH4K
    • 11.60.3. Secretions
  • 11.61. Reliance Life Sciences Pvt. Ltd.
    • 11.61.1. CardioRel
  • 11.62. Reneuron Group plc
    • 11.62.1. CTX Cell Line
    • 11.62.2. hRPC
    • 11.62.3. Exosome Platform
  • 11.63. Stemedica Cell Technologies Inc.
    • 11.63.1. BioSmart Technology
    • 11.63.2. Clinical Pipeline
  • 11.64. StemGen Therapeutics
    • 11.64.1. Lipokraft
    • 11.64.2. Lipokraft Advance
    • 11.64.3. Amniokraft
  • 11.65. Stempeutics Research Pvt. Ltd.
    • 11.65.1. Stempeucel
    • 11.65.2. Stempeucare
    • 11.65.3. Stempeutron
  • 11.66. Stratatech Corp.
    • 11.66.1. StrataGraft
    • 11.66.2. ExpressGraft
  • 11.67. ThermoFischer Scientific Inc.
  • 11.68. TiGenix N.V.
    • 11.68.1. TiGenix's Pipeline
  • 11.69. U.S. Stem Cell Inc.
    • 11.69.1. MyoCell
    • 11.69.2. MyoCell SDF-1
    • 11.69.3. AdipoCell
  • 11.70. Vericel Corporation
    • 11.70.1. Ixmyelocel-T
    • 11.70.2. MACI
    • 11.70.3. Epicel
    • 11.70.4. Carticel
  • 11.71. ViaCyte Inc.
    • 11.71.1. VC-01
    • 11.71.2. VC-02
  • 11.72. Xintea AB
    • 11.72.1. XINMARK
    • 11.73. Zen-Bio Inc.

INDEX OF FIGURES

  • FIGURE 3.1: Major Indications of Advanced Therapy Clinical Trials
  • FIGURE 4.1: Differentiation of Stem Cells into Adult Specialized Cells
  • FIGURE 4.2: Differentiation of Embryonic Stem Cells into Adult Specialized Cells
  • FIGURE 4.3: Differentiation of Induced Pluripotent Stem Cells into Adult Specialized Cells
  • FIGURE 4.4: Types of Specialized Cells Derived from Stem Cells
  • FIGURE 4.5: Applications of Stem Cells
  • FIGURE 5.1: Types of Common Diseases Registered for MSC-Based Cell Therapy
  • FIGURE 5.2: Some Mechanisms of MSCs in Therapeutic Application
  • FIGURE 5.3: Steps in the Manufacturing Process of MSCs
  • FIGURE 6.1: Clinical Trials of MSCs Classified by Disease Type
  • FIGURE 7.1: Stem Cell Research Publications Landscape
  • FIGURE 7.2: Number of Published Scientific Papers on MSCs
  • FIGURE 7.3: Number of Publications on MSCs by Major Applications, 2016
  • FIGURE 8.1: Currently Active Clinical Trials using MSCs
  • FIGURE 8.2: MSC-Based Clinical Trials by Geography
  • FIGURE 8.3: Sources of MSCs used in Current Clinical Trials
  • FIGURE 8.4: Diseases Addressed by MSCs in the Ongoing Clinical Trials
  • FIGURE 9.1: Value of Deals Undertaken by Big Pharma in Gene and Cell Therapy Sector, 2016
  • FIGURE 9.2: Geographical Distribution of Cell Therapy Companies
  • FIGURE 10.1: Global Market for Mesenchymal Stem Cells and Products, 2016-2022
Back to Top